These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38696696)

  • 1. Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA.
    Hagiwara M; Divino V; Munnangi S; Delegge M; Park S; Marins EG; Ren K; Strange C
    J Comp Eff Res; 2024 Jun; 13(6):e230186. PubMed ID: 38696696
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States.
    Sieluk J; Slejko JF; Silverman H; Perfetto E; Mullins CD
    Orphanet J Rare Dis; 2020 Sep; 15(1):260. PubMed ID: 32967697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Database Analysis of Liver-Related Clinical Events in Adult and Pediatric Patients with Alpha-1 Antitrypsin Deficiency in the United States.
    Hagiwara M; Divino V; Munnangi S; Delegge M; Park S; Marins EG; Ren K; Strange C
    Hepat Med; 2024; 16():55-64. PubMed ID: 39070302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-1 Antitrypsin Deficiency-Associated Clinical Manifestations and Healthcare Resource Use in the United States.
    Herrera EM; Joseph C; Brouwer ES; Gandhi V; Czorniak M
    COPD; 2021 Jun; 18(3):315-324. PubMed ID: 34036848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver disease progression in patients with alpha-1 antitrypsin deficiency and protease inhibitor ZZ genotype with or without lung disease.
    Wu T; Hagiwara M; Gnass E; Barman H; Sasson D; Treem W; Ren K; Marins EG; Karki C; Malhi H
    Aliment Pharmacol Ther; 2023 Nov; 58(10):1075-1085. PubMed ID: 37718576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM
    BMC Health Serv Res; 2024 May; 24(1):691. PubMed ID: 38822336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study.
    Borate U; Seiter K; Potluri R; Mazumder D; Chevli M; Prebet T; Gaugler L; Strocchia M; Vasconcelos A; Sieluk J
    Adv Ther; 2024 Nov; 41(11):4049-4064. PubMed ID: 39240504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
    Flanigan JA; Yasuda M; Chen CC; Li EC
    Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and direct medical costs associated with index and recurrent
    Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
    J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
    [No Abstract]   [Full Text] [Related]  

  • 10. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients.
    Karl FM; Holle R; Bals R; Greulich T; Jörres RA; Karch A; Koch A; Karrasch S; Leidl R; Schulz H; Vogelmeier C; Wacker ME;
    Respir Res; 2017 Apr; 18(1):60. PubMed ID: 28416015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [No Abstract]   [Full Text] [Related]  

  • 12. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
    Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
    J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health care resource utilization and costs across stages of amyotrophic lateral sclerosis in the United States.
    Stenson K; Chew S; Dong S; Heithoff K; Wang MJ; Rosenfeld J
    J Manag Care Spec Pharm; 2024 Nov; 30(11):1239-1247. PubMed ID: 39471269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource utilization and costs associated with hepatitis A in the United States: a retrospective database analysis.
    Samant S; Chen E; Carias C; Kujawski SA
    J Med Econ; 2024; 27(1):1046-1052. PubMed ID: 39092467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
    Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
    Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
    [No Abstract]   [Full Text] [Related]  

  • 19. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.